Izotropic Corporation | News
  • CSE: IZO
  • OTCQB: IZOZF
  • FSE: 1R3
Menu
6/13/2025
Izotropic Provides Marketing Update
VIEW
6/10/2025
Izotropic Updates License Agreement Terms with University of California
VIEW
5/16/2025
Izotropic’s U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update
VIEW
4/2/2025
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
VIEW
3/25/2025
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
VIEW
3/10/2025
Izotropic to Present at Investor Conference March 13th
VIEW
2/19/2025
FDA Sets Meeting Date with Izotropic
VIEW
2/14/2025
Izotropic Closes Non-Brokered Private Placement
VIEW
2/7/2025
Izotropic Announces Non-Brokered Private Placement- February 2025
VIEW
2/6/2025
Izotropic Reschedules Investor Conference Presentation to March 13th
VIEW
2/3/2025
Izotropic to Present at Investor Conference February 6th
VIEW
1/29/2025
Izotropic Announces Timelines and Milestones to IzoView Product Launch
VIEW
1/17/2025
Izotropic Featured in Announcement of Research and Markets’ U.S. Breast Cancer Analysis and Forecast
VIEW
1/15/2025
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions
VIEW
1/9/2025
Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening
VIEW
12/31/2024
Izotropic Announces AGM Results - 2024
VIEW
12/4/2024
Izotropic Provides Update On Annual General Meeting Materials and Voting Procedures
VIEW
11/13/2024
Izotropic Corporation Announces Non-Brokered Private Placement- November 2024
VIEW
8/23/2024
Izotropic Announces Regulatory Approval Plans to Launch IzoView for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU
VIEW
7/17/2024
Izotropic Amends Promissory Note Agreement With Primary Lender
VIEW
6/14/2024
Izotropic Announces Closing of First Tranche of Non-Brokered Private Placement
VIEW
6/6/2024
Izotropic Corporation Announces Non-Brokered Private Placement- June 2024
VIEW
1/30/2024
Izotropic Receives Response From U.S. FDA
VIEW
1/8/2024
Izotropic Provides Regulatory and Operational Updates
VIEW
12/22/2023
Izotropic Announces AGM Results- 2023
VIEW
11/1/2023
Izotropic Completes Pre-Submission Meeting With U.S. FDA
VIEW
9/27/2023
Izotropic Confirms FDA Pre-Submission Meeting Date
VIEW
9/20/2023
Izotropic Closes Non-Brokered Private Placement- September 2023
VIEW
9/13/2023
Izotropic Corporation Announces Non-Brokered Private Placement- September 2023
VIEW
9/6/2023
Izotropic Files Class II Pre-Submission with FDA & Releases Details On Predicate Devices
VIEW
6/27/2023
Izotropic Engages Market Awareness Consultant
VIEW
6/20/2023
Izotropic Modifies Market Approval Pathway & Strategy
VIEW
6/8/2023
Izotropic CEO Resigns
VIEW
5/15/2023
Izotropic Completes QSUB Meeting with FDA Regarding Clinical Study Acceleration
VIEW
4/27/2023
Izotropic Provides Business Update
VIEW
3/29/2023
Izotropic to Extend Period for Unsecured Loans
VIEW
2/23/2023
Izotropic’s Technical & Scientific Team Members Advocate for Commercialization of Breast CT Technology
VIEW
1/13/2023
Izotropic’s IzoView Breast CT Device To Be Featured On Advancements TV Show In USA
VIEW
1/12/2023
Izotropic Creates Compensation Committee and Adopts Charter
VIEW
1/9/2023
Izotropic Releases First Video of IzoView
VIEW
1/4/2023
Izotropic Reports Board Meeting Results
VIEW